Tele: 561.316.3330
Breaking Medical Device News

Monday, September 27, 2021
HomeClinical Trials, Studies, Data UpdatesFAST BioMedical Successfully Completes Open-Label Proof-of-Concept Study for Measuring Interstitial Volume

FAST BioMedical Successfully Completes Open-Label Proof-of-Concept Study for Measuring Interstitial Volume

FAST BioMedical, a privately held, late-clinical-stage medical technology company, today announces the completion of an open-label study using its technology in chronic dialysis patients.

The goal of the study was to use FAST BioMedical’s technology to determine total volume removal before and after dialysis treatment by measuring both plasma volume and interstitial volume.

Conducted at the Richard L. Roudebush VA Medical Center in Indianapolis, the study evaluated the safety, tolerability and performance of the FAST Technology in chronic dialysis patients with extremely reduced or no kidney function. Based on how FAST BioMedical’s technology works, this was the best initial patient population to establish clinical Proof-of-Concept.

Despite challenges due to the pandemic, the enrollment was successfully completed on time and all study endpoints were met. Specifically, the study demonstrated the company’s second-generation fluorescence instrument works well, clinical Proof-of-Concept in interstitial volume measurement, and the successful implementation of FAST BioMedical’s technology in the clinical workflow for dialysis patients and dialysis units.

“Objectively measuring volume and changes in volume is a critically important unmet need in clinical medicine,” said Arjun D. Sinha, MD, who served as the primary investigator in this study. “FAST BioMedical’s technology performed well in this study, and we look forward to reporting the results in the coming months.”

The clinical samples collected during this study were analyzed at the Indiana Biosciences Research Institute building in the 16 Tech Innovation District. FAST BioMedical has wet lab space in 16 Tech and was able to analyze the collected samples using their second-generation fluorescence instrument in a qualified lab environment.

“Over the course of 2020 and early 2021, the 16 Tech space has allowed us to concentrate on the further refinement of our instruments by providing a proper laboratory environment to validate and test our devices,” said Dan Meier, VP of product development at FAST BioMedical. “The facility itself has given us access to appropriate FDA-compliant resources in one efficient location.”

Although this was a preliminary Proof-of-Concept study for measuring interstitial volume in dialysis patients, the potential impact of measuring interstitial volume in all patients where volume is being managed is profound.  Many clinicians believe measurement of interstitial volume is one of the key critical parameters in these patients.

Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

ProSomnus® Sleep Technologies Adds John E. Remmers, MD, to Leadership Team

Dr. John E. Remmers will provide expert medical and strategic guidance on a range of initiatives, including research and development, regulatory clearances, company strategy, medical education, and clinical investigations.

Nanox to Announce Zebra Medical Vision Secures 8th 510K FDA Clearance for its Coronary Artery Calcium (CAC) Solution as Part of Its Population Health Offering

On August 10th, 2021 Nanox announced that it had entered into an acquisition agreement via merger with Zebra Medical Vision LTD.

Christopher Joyce Joins Miach Orthopaedics as VP & CFO

Christopher Joyce has joined as vice president and chief financial officer, and Kevin Sidow has been appointed to the company’s board of directors.

NGMedical GmbH Receives FDA Clearance for Its AM Titanium Lumbar Interbody BEE® PLIF

The BEE® PLIF cage has been created to benefit from additive manufacturing features. The purposefully designed honeycomb endplate design reduces the risk of subsidence, while allowing fusion.

Recombinant Technologies is Raising Capital to Roll Out a Game Changing Alzheimer’s Treatment

Recombinant Technologies is focused on treating the root cause of Alzheimer's Disease delivering a huge improvement in the quality of life of those afflicted.

Tyber Medical Reaches Agreement to Acquire CatapultMD

Once the acquisition is complete, Tyber Medical will own and operate a combined 100,000-square feet of manufacturing space between its Pennsylvania headquarters and Florida-based facilities.

Kleiner Device Labs Receives FDA Market Clearance for KG2 Surge Flow-Thru Interbody System

The system maximizes total bone graft delivery volume, better distributes graft bilaterally into the intervertebral disc space, and streamlines the implant delivery, positioning, and grafting process for TLIF and PLIF spinal fusion procedures.

Matthew Cranfill New ExtriCARE USA Director Of Clinical Services

"Matt's impressive experience and skillset easily made him our top pick," said Peter Mason, President of ExtriCARE USA.

By using this website you agree to accept Medical Device News Magazine Privacy Policy